Tevogen(NASDAQ) TVGNW

Market CapN/A

Since IPO (2022)-89%

5 YearN/A

1 Year-17%

1 Month+9%

$0.05

-6.54%

-0.00Today

Tevogen last closing stock price
Metric	Price	Date
Last close	USD 0.05	2026-08-31

Tevogen stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+10.56%	USD 0.05	2026-08-24
1 month	+9.11%	USD 0.05	2026-07-31
3 month	+17.03%	USD 0.04	2026-06-02
Year to date	+18.42%	USD 0.04	2025-12-31
1 year	-16.71%	USD 0.06	2025-08-29
3 year	-28.61%	USD 0.07	2023-08-31
Since inception	-88.9%	USD 0.45	2022-01-03

Tevogen Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$21.61M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.88 (Low)

Dividend

$0.00

Beta (Volatility)

-1.88 (Low)

Price

$0.05

Volume

209,419

Open

$0.05

Price

$0.05

Volume

209,419

Open

$0.05

Previous Close

$0.05

Daily Range

$0.05 - $0.05

52-Week Range

$0.03 - $0.07

Estimated Earnings Date

Nov 24, 2026

Dividend

$0.00

Beta (Volatility)

-1.88 (Low)

Price

$0.05

Volume

209,419

Open

$0.05

Previous Close

$0.05

Daily Range

$0.05 - $0.05

52-Week Range

$0.03 - $0.07

Estimated Earnings Date

Nov 24, 2026

TVGNW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tevogen

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company dedicated to developing ready-to-use, precision T cell therapies. The company focuses on addressing unmet medical needs in virology, oncology, and neurological conditions, with its flagship product, TVGN 489, targeting severe cases of acute COVID-19 and long COVID.

Products and Services

Precision T cell therapies for acute COVID-19 and long COVID
Research and development in oncology and neurological conditions
Innovative solutions for unmet medical needs in healthcare

Growth Outlook

Strong focus on precision medicine aligns with industry trends
Potential for significant market share in T cell therapy sector
Ongoing clinical trials may lead to breakthrough treatments

Financial Highlights

Recent quarterly net income of -$5.45 million reflects ongoing R&D investments
Cash and cash equivalents increased to $692,305 in Q1 2026
Trailing twelve months (TTM) revenue remains at $0, indicating early-stage development

Tevogen Bio Holdings Inc. operates in a rapidly evolving biotechnology landscape, focusing on innovative therapies that leverage the body's immune system. The company's commitment to precision medicine positions it well for future growth, particularly as the demand for effective treatments in the wake of the COVID-19 pandemic continues to rise. With a robust pipeline and ongoing clinical trials, Tevogen Bio Holdings Inc. is poised to make significant contributions to the healthcare sector. The financial data indicates a focus on research and development, which is essential for long-term success in the biotechnology industry.

AI Generated • Aug 8, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Warren, NJ 07059, US

TVGNW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

248.50%

Return on Capital

N/A

Return on Assets

-457.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

209.42K

Avg. Volume

263.01K

Financials (TTM)

Gross Profit

-$204.98K

Operating Income

-$21.40M

EBITDA

-$20.95M

Operating Cash Flow

-$11.57M

Capital Expenditure

-$64.43K

Free Cash Flow

-$11.63M

Cash & ST Invst.

$1.08M

Total Debt

$3.04M

Tevogen Performance Analysis

Tevogen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Tevogen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	2.0%
Q4	2025-12-31	20.0%
Q1	2026-03-31	-34.2%
Q2	2026-06-30	5.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$60.14K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$5.76M

-4.7%

EBITDA

-$5.60M

-2.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$1.08M

+57.9%

Total Debt

$3.04M

-59.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$1.06M

-80.9%

Short Term Debt

$1.98M

+0.0%

Return on Assets

-4.57%

N/A

Return on Invested Capital

15.04%

N/A

Free Cash Flow

-$3.01M

+5.8%

Operating Cash Flow

-$3.01M

+5.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MRKRMarker Therapeutics, Inc.

MRKRMarker Therapeutics, Inc.$1.33-2.92%

COCPCocrystal Pharma, Inc.

COCPCocrystal Pharma, Inc.$1.16+5.45%

PHIOPhio Pharmaceuticals Corp.

PHIOPhio Pharmaceuticals Corp.$1.09-3.54%

APMAptorum Group Limited

APMAptorum Group Limited$8.26-14.84%

MBIOMustang Bio, Inc.

MBIOMustang Bio, Inc.$0.54-0.02%

DWTXDogwood Therapeutics, Inc.

DWTXDogwood Therapeutics, Inc.$2.58-2.64%

CINGCingulate Inc.

CINGCingulate Inc.$5.17-2.91%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.92+0.00%

WETOWetour Robotics

WETOWetour Robotics$5.48-0.04%

INTCIntel

INTCIntel$89.51+0.00%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.67+0.02%

Questions About TVGNW

What is the current price of Tevogen?

Tevogen is trading at $0.05 per share.

What is the 52-week range for Tevogen?

Over the past 52 weeks, Tevogen has traded between $0.03 and $0.07.

How much debt does Tevogen have?

Tevogen total debt is unavailable.

How much cash does Tevogen have on hand?

Tevogen does not have cash on hand data available.

What is Tevogen’s dividend yield?

Tevogen does not currently have a dividend yield.

Tevogen(NASDAQ) TVGNW

Tevogen Financials at a Glance

TVGNW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Tevogen

TVGNW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Tevogen Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TVGNW

What is the current price of Tevogen?

What is the 52-week range for Tevogen?

How much debt does Tevogen have?

How much cash does Tevogen have on hand?

What is Tevogen’s dividend yield?

Premium Investing Services